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Rationale: Vitamin D and vitamin D binding protein (DBP) have been associated with COPD and
FEV1. There are limited data regarding emphysema and vitamin D and DBP.
Objective: This is a pilot study of a portion of the subjects in the Evaluation of COPD Longitu-
dinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study designed to examine the
relationship between vitamin D status, DBP, FEV1 and emphysema in COPD patients.
Methods: We measured serum 25(OH)D and DBP in 498 ECLIPSE subjects. Subjects were distrib-
uted amongst smoker controls, non-smoker controls, and GOLD stages 2, 3 and 4. Within each.edu, lrichard@unmc.edu (S. Rennard).
to the study.
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This study demonstrates a
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conditions, and inflammatory bGOLD stage, the subjects were equally divided amongst high and low emphysema burden. The
associations between 25(OH)D, DBP, and free vitamin D with FEV1, CT-defined emphysema,
biomarkers and clinical data including CT-measured bone attenuation were assessed.
Measurements: 25(OH)D and DBP were measured using tandem mass spectroscopy and
competitive enzyme-linked immunosorbent assay, respectively,
Main result: 25(OH)D was correlated with FEV1 (p Z 0.01) and with severity of emphysema
(p < 0.01). 25(OH)D was also associated with six-minute walk (p Z 0.02), bronchodilator
response (pZ 0.04), and Clara cell secretory protein (CC-16) (pZ 0.01). 25(OH)D levels were
not associated with CT-measured bone attenuation, however DBP was associated with bone
attenuation in subjects with emphysema. DBP was not associated with FEV1 or emphysema.
25(OH)D and DBP were inversely associated (p Z 0.01).
Conclusion: This is the first study to demonstrate a relationship between emphysema and
vitamin D. We also provide further evidence for a relationship between vitamin D and FEV1.
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Chronic Obstructive Pulmonary Disease (COPD) is presently
the third leading cause of death in the United States [1].
COPD, and many of its co-morbid conditions, are associated
with vitamin D status. Vitamin D deficiency is recognized as
a widespread problem among adults in general, and in
COPD patients specifically [1,2]. The association of vitamin
D deficiency with poor pulmonary health is becoming more
well-defined. Studies such as NHANES have identified a
positive relationship between vitamin D status and pulmo-
nary function [3,4]. Whether Vitamin D is associated with
emphysema remains unknown. Vitamin D deficiency is also
associated with the extra-pulmonary features of COPD. For
example, vitamin D deficiency can impair host defense, and
vitamin D replacement can improve innate immunity [5,6].
Vitamin D deficiency has also been associated with other
clinical features of COPD, such as 6-min walking distance,
and co-morbidities, including osteoporosis [7e9] as well as
poor adherence and outcome of pulmonary rehabilitation
[10]. While one recent study did not demonstrate an effect
of vitamin D supplementation on exacerbations in a popu-
lation of 182 COPD patients, supplementation in a subset of
patients with severe vitamin D deficiency was associated
with a reduction in the rate of exacerbations [11].In contrast to the direct relationship of 25(OH)D levels
with lung function, vitamin D binding protein (DBP) levels
havebeen reported to be inversely related to FEV1 in patients
with alpha-1 anti-trypsin deficiency [12]. DBP has also been
implicated as a candidate in the pathogenesis of COPD due to
its role in macrophage activation and neutrophil chemotaxis
[13]. Serum DBP circulates in concentrations that are 20-fold
higher than 25(OH)D concentrations, and bind more than 88%
of 25(OH)D. Owing to the avid binding affinity of DBP to
vitamin D, a molar concentration ratio can be calculated to
represent the “free vitamin D” metabolite concentration
[14e17]. Free vitamin D levels may be of interest, as protein-
bound vitamin D metabolites may have limited access to
target cells, and free levels may provide a better estimate of
the biologically active component of vitamin D.
The current study was designed to address several key
questions exploring the role of vitamin D measures in out-
comes related to lung function, lung structure, and COPD
related conditions. First, we addressed the question of
whether vitamin D is associated with emphysema as well as
with FEV1 in COPD patients. Second, we assessed if DBP
levels were associated with FEV1 or with emphysema and,
using DBP levels, we assessed the relationships with
calculated free Vitamin D. Finally, we assessed the rela-
tionship of these measures of Vitamin D with selected
clinical features of COPD.
Methods
Study population
This analysis is based on data from 498 subjects from the
Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints study (ECLIPSE). A visual breakdown of
the study subjects is provided in Fig. 1. Demographic fea-
tures of these subjects are presented in Table 1. Subjects
included 75 smoker and 75 non-smoker controls and three
groups of 116 subjects each with GOLD airflow limitation
severity stage 2, 3 and 4. The latter three groups included
the 58 subjects with the highest and the 58 subjects with
the lowest CT emphysema scores (% of lung voxels below
950 Hounsfield units) in each GOLD stage. Stored serum
samples from visit 7 of the ECLIPSE study, which corre-
sponded to 2½ years after study entry, were assessed.
498 Subjects
COPD Subjects
116 GOLD Stage II
116 GOLD Stage III
116 GOLD Stage IV
75
Smoker  
Controls
75 Non-Smoker 
Controls
Figure 1 Subject distribution. Subjects were selected from
the entire Eclipse cohort to have a range of FEV1 values (GOLD
2, 3 and 4) and to have a range of emphysema severities within
each GOLD group stage. Both smoking and non-smoking con-
trols were included.
1580 I. Berg et al.Complete details of ECLIPSE study participants and study
design have been previously described [18].
Measurements
25(OH)Dwasmeasuredwith liquideliquid extraction, tandem
mass spectroscopy (ABSciex 4000 tandem mass spectropho-
tometer, ABSciex, Massachusetts). Values lower than the
minimal reporting threshold (<10 ng/mL) were given a value
of 5 ng/ml to facilitate analysis. DBP was measured with an
internally validated competitive enzyme linked immu-
noabsorbant assay (ELISA) using commercially available re-
agents and optimized as described [19]. Pre- and post-
bronchodilator FEV1 and FVC were measured concurrently
with the serum sampling. CT-scan defined emphysema was
assessedat year 3, thenearest assessmentpoint to serumdata
for smoker controls and COPD subjects, and at study entry in
non-smoker controls. Quantitative assessment of emphysemaTable 1 Population demographics.
% or mean (SD) Non-smoking
controls (n Z 75)
Sm
co
Age (years) 54.8 (8.7) 54
Male 40.0 56
Race
White/Caucasian/European 96.0 10
White/Arabic/North African 1.3 0.
African American/African 2.7 0.
Body mass index (kg/m2) 26.8 (4.8) 27
Smoking status
Current 0.0 56
Former 13.3 44
Never 86.7 0.
Lifetime smoking (pack years) 0.4 (1.4) 32
FEV1 pre-dose (L) 3.1 (0.7) 3.
FEV1 post-dose (L) 3.2 (0.7) 3.
% Predicted FEV1 Pre- Bronchodilator 107.8 (13.7) 99
% Predicted FEV1 post-dose 110.7 (13.3) 10
Forced vital capacity pre-dose (L) 4.0 (1.0) 4.
Forced vital capacity post-dose (L) 4.0 (1.0) 4.
% Low attenuation area (>950HU) 3.9 (4.5) 3.was performed by attenuationmask analysis using a threshold
of 950 Hounsfield Units (Pulmonary Workstation 2.0, VIDA
Diagnostics, Iowa City, IA, USA) and expressed as the percent
of low attenuation areas (%LAA). Serum free vitamin D was
estimatedbymolar concentration ratio indexof 25(OH)D:DBP.
Additional biomarker and clinical data evaluated for
their relationship with vitamin D measures are given in
Table 2, and were measured at study baseline. Six-minute
walk data were only available on COPD subjects, and
were taken from the year 3 visit. SGRQ data were used from
year 3 visit. GOLD grouping (AeD) was performed and
characterized as noted in most recent GOLD document [20]
with Modified Medical Research Council dyspnea score
(MMRC) as the symptomatic measure.
Low-dose CT scans of the chest were performed as
described [18]. Bone attenuation was measured on CT using
the software VOXAR 3D version 16.0 as described previously
[21]. Briefly, the mean bone attenuation of thoracic
vertebrae 4, 7 and 10 (T4, T7 and T10) were determined by
placing circular regions of interest in the central parts of
the vertebral bodies. The average bone attenuation was
calculated and expressed as a single unit expressed in
Hounsfield Units.
Statistical analysis
Associations between pairs of variables of interest were
evaluated using Spearman correlation coefficients. Linear
regression models were used to further examine possible
associations and to test for interactions across groups of
subjects. ANOVA models were used to test for differences in
means of various measures across groups based on level of
25(OH)D. Multivariate models for each of the primary
outcome measures were run controlling for the confounders
of age, sex, BMI, smoking status, and season. A fixed effectsoking
ntrols (n Z 75)
COPD cases
GOLD 2
(n Z 116)
GOLD 3
(n Z 116)
GOLD 4
(n Z 116)
.8 (8.9) 62.6 (8.1) 62.2 (7.5) 61.5 (7.5)
.0 53.5 69.0 74.1
0.0 98.3 97.4 96.6
0 0.0 0.0 0.9
0 1.7 1.7 2.6
.1 (4.3) 25.5 (4.2) 25.6 (6.0) 25.2 (6.0)
.0 32.8 39.7 31.9
.0 67.2 60.3 68.1
0 0.0 0.0 0.0
.7 (23.7) 41.1 (20.7) 43.4 (23.2) 48.8 (28.3)
1 (0.8) 1.5 (0.5) 1.0 (0.4) 0.7 (0.3)
2 (0.8) 1.7 (0.5) 1.1 (0.4) 0.8 (0.3)
.1 (13.4) 55.9 (13.6) 36.1 (11.1) 23.8 (7.6)
3.6 (13.7) 61.7 (14.2) 39.3 (11.4) 25.6 (7.9)
1 (1.1) 3.1 (0.9) 2.6 (0.8) 2.3 (0.7)
2 (1.1) 3.3 (0.9) 2.9 (0.8) 2.5 (0.7)
3 (3.2) 18.4 (17.9) 25.1 (21.2) 30.4 (14.8)
Table 2 Vitamin D, biomarkers, and clinical
characteristics.
Spearman correlation coefficients
P-value
Number of observations
25(OH)D
(ng/mL)
Vitamin D
binding
protein
(mg/dL)
Free
vitamin D
ratio
SGRQ score 0.183 0.023 0.158
<0.001 0.621 <0.001
477 482 477
6-min walk 0.136 0.034 0.156
0.02 0.55 0.01
313 316 313
Bronchodilator
reversibility
0.095 0.058 0.042
0.04 0.20 0.36
488 493 488
Fibrinogen (mg/dL) 0.064 0.066 0.020
0.16 0.14 0.66
491 496 491
Clara cell secretory
protein (ng/mL)
0.181 0.036 0.164
<0.01 0.43 <0.01
485 490 485
C-reactive
protein (mg/L)
0.080 0.046 0.083
0.08 0.32 0.07
478 482 478
Surfactant
protein D (ng/mL)
0.094 0.003 0.068
0.04 0.95 0.13
485 490 485
Total neutrophils 0.070 0.075 0.092
0.13 0.10 0.04
482 487 482
White blood
cell count
0.041 0.100 0.086
0.36 0.03 0.06
482 487 482
Body mass
index (kg/m2)
0.052 0.019 0.022
0.25 0.67 0.63
492 497 492
Fat free mass 0.023 0.085 0.037
0.61 0.06 0.42
484 489 484
CT-measured
bone attenuation
(mean of T4,
T7, T10
0.033 0.053 0.052
0.50 0.28 0.30
407 411 407
Figure 2 Relationship between FEV1 and Serum 25(OH)D.
25(OH)D was measured as described in methods and related to
FEV1 measured at the same visit. Panel A: direct relationship
between the variables. The relationship was significant
(r Z 0.116, p Z 0.01). Panel B: Subjects were grouped by
vitamin D level (<10, severely deficient, 10e20, deficient;
20e30; insufficient, and >30; sufficient. There were reductions
in FEV1 associated with vitamin D status that were most
marked in the severely deficient group. (Group comparison to
sufficient group (>30) p Z 0.0062).
Vitamin D lung function and structure in COPD 1581analysis examining GOLD subject group based on mMRC,
exacerbation history and FEV1 was performed using Group D
(high risk,more symptoms) as a reference group. All analyses
were conducted using SAS v9.2 (The SAS Institute, Cary, NC).
Results
Serum 25(OH)D
The mean 25(OH)D level of the cohort, including COPD
subjects and controls, was 24.0 ng/mL. Vitamin Dinsufficiency, defined as 25(OH)D levels of <30 ng/mL, was
present in 69% of the cohort, and deficiency, defined as
25(OH)D levels of <20 ng/mL, was present in 39% of the
population. Severe deficiency (<10 ng/mL) occurred in
8.7% of subjects. Among the groups, the only mean 25(OH)D
levels that differed significantly from each other were
GOLD 4 group compared to smoking controls (22.18 vs.
27.99 ng/ml, respectively), and GOLD 3 group vs. smoking
controls (21.9 vs. 27.99 ng/mL, respectively).
As expected, 25(OH)D levels were significantly associ-
ated with FEV1 (Fig. 2a, r Z 0.116, p Z 0.01). The effect
was primarily driven by individuals with the lowest levels of
Vitamin D, which is better visualized when Vitamin D levels
Figure 3 Relationship between emphysema and Serum
25(OH)D. 25(OH)D was measured as described in methods and
related to emphysema assessed by CT scan (see methods),
which was performed on a visit 6 months later. Panel A: direct
relationship between the variables. The relationship was sig-
nificant (r Z 0.141, p Z <0.01). Panel B: Subjects were
grouped by vitamin D level (<10, severely deficient, 10e20,
deficient; 20e30; insufficient, and >30; sufficient. There was
increased emphysema severity associated with vitamin D status
that was most marked in the severely deficient group. (Group
comparison to replete group (>30) p Z 0.0018).
1582 I. Berg et al.are grouped (Fig. 2b). The association remained significant
after adjustment for confounders (p Z 0.006). Lower
25(OH)D levels were also significantly associated with
emphysema (r Z 0.141, p < 0.01) (Fig. 3). As with FEV1,
the relationship between 25(OH)D and emphysema was
most marked for individuals with lower 25(OH)D levels, and
this is better visualized when the vitamin D levels are
grouped (Fig. 3b). Similar to FEV1, the relationship
remained significant after adjustment for confounders
(p Z 0.007). When only the COPD subjects were assessed,
the relationship between 25(OH)D and FEV1 and emphy-
sema was no longer significant (Supplementary Table E1).
Lung capacity measures were also assessed. After control-
ling for confounders, both post-dose FVC and predicted
normal FVC were positively associated with 25(OH)D levels
(p Z 0.024 and 0.009, respectively).
Vitamin D binding protein
DBP was not associated with either FEV1 or emphysema,
(Supplemental Figure E1). However, DBP was negatively
associated with serum 25(OH)D level (Fig. 4, r Z 0.122,
p Z 0.01).
Free vitamin D
Direct measurement of free Vitamin D is problematic.
However, as the dissociation constant of Vitamin D from
DBP is well established, it is possible to estimate free
vitamin D from the concentration of total Vitamin D and
DBP. Free vitamin D was associated with 25(OH)D (rZ 0.81,
p < 0.0001) and with DBP (r Z 0.63, p < 0.0001). Using
this calculated estimate, no association was observed be-
tween either FEV1 (r Z 0.079, p Z 0.08) or emphysema
(r Z 0.082, p Z 0.07, Supplemental figure E2).
Clinical features and selected biomarkers
Because vitamin D has been previously associated with
certain systemic effects of COPD, the relationships between
vitamin D, DBP, free vitamin D and selected clinical features
and biomarkers were assessed in order to provide additional
information on vitamin D and extra-pulmonary features of
COPD (Table 2). There were significant associations be-
tween 25(OH)D and SGRQ, Clara cell secretory protein-16,
surfactant protein D, 6 min walking distance and broncho-
dilator reversibility. For 6 min walking distance and SGRQ,
where the associations were somewhat stronger, a dispro-
portionate association of impairment was associated with
very severe depletion of vitamin D (Fig. 5). This was much
less apparent for bronchodilator responsiveness (Fig. 5).
25(OH)D levels were not associated with CT measured bone
attenuation (Supplemental Figure E3, Supplemental Table
E2). After adjustment for BMI and smoking status, the as-
sociation between bone attenuation and 25(OH)D remained
non-significant. However, in subjects with emphysema, DBP
levels were associated with bone attenuation measure-
ments (r Z 0.20, p Z 0.02) (Fig. 6).
A significant relationship was observed between DBP and
total WBC count (p Z 0.03), and free vitamin D with SGRQ
(p < 0.001), bronchodilator response (pZ 0.05), 6 min walk(p Z 0.01), SGRQ (p  0.001), clara cell secretory protein
(p  0.001) and total neutrophil count (pZ 0.04) (Table 2).
It was also of specific interest to assess the relationship
between Vitamin D and body composition. Interestingly,
neither fat free mass nor body mass index was significantly
related to 25(OH)D, DBP or free Vitamin D (Supplementary
Table E3).
Figure 4 Relationship between Vitamin D Binding Protein
and 25(OH)D. Vitamin D binding protein (DBP) and 25(OH)D
were measured as described. Values of 25(OH)D below the limit
of detectability (10 ng/ml) were assigned a value of 5 ng/ml.
Vertical axis: DBP, horizontal axis: 25(OH)D. The relationship
was significant (r Z 0.122, p Z 0.01).
Figure 5 Relationship between 6 min walk distance, bronchodi
measured as described in methods. Subjects were grouped by vita
insufficient, and >30; intact. Panel A: 6 min walking distance; Pan
Vitamin D lung function and structure in COPD 1583Vitamin D and GOLD severity
The most recent GOLD Strategy document has suggested
that COPD patients should be classified into 4 groups based
on presence of low lung function, frequent exacerbations,
and severity of symptoms [20]. Using the mMRC to gauge
symptoms, subjects were classified into 4 groups corre-
sponding to the current GOLD strategy. 25(OH)D and free
vitamin D levels were significantly lower in group D when
compared to controls. DBP was not different among the
groups. (Fig. 7, see also Supplementary Figures E4, Tables
E4 and E5).
Discussion
In addition to confirming the previously established rela-
tionship between 25(OH)D with FEV1 [3,4] and 6-min walk
distance [7,9], we provide new evidence establishing a
relationship between 25(OH)D and emphysema. Interest-
ingly, the relationship with emphysema was seen in the
entire population, but was not seen quantitatively in the
COPD subject group. This resembles the effect of ever
smoking vs. amount smoked [22]. In that setting, smoking
has been suggested to initiate a process that leads tolator responsiveness, SGRQ and Serum 25(OH)D. 25(OH)D was
min D level (<10, severely deficient, 10e20, deficient; 20e30;
el B: Bronchodilator Respose; Panel C: SGRQ
Figure 6 Relationship between VDBP and CT measured bone
attenuation emphysema is defined here as those GOLD subjects
with above-median measures for emphysema within their
respective GOLD classes, DPB levels were associated with CT
measured bone attenuation (mean of T4, T7, and T10)
(r Z 0.20, p Z 0.02).
1584 I. Berg et al.emphysema, but continued smoking is not required for its
emphysema progression. We also demonstrate a significant
relationship between vitamin D with SGRQ, bronchodilator
responsiveness and selected biomarkers of COPD.
Consistent with previous studies [1,2], this study docu-
ments a high prevalence of vitamin D deficiency and
insufficiency in a population of COPD patients and controls.Figure 7 Vitamin D aReduced FEV1 has been associated with lower 25(OH)D
levels in both the general population and COPD patients
[3,4,12]. However, these findings were not replicated by
Shaheen and colleagues [23]. Our results continue to pro-
vide evidence of a relationship between lung function and
25(OH)D in the general population, but, like Shaheen we
did not find a significant correlation between 25(OH)D and
FEV1 in the COPD population. There are some important
differences among these studies. Janssens, who found a
relationship between FEV1 and 25(OH)D in a COPD popu-
lation, it included mostly elderly men, while both the
current study and that of Shaheen included more women. In
addition, Janssens excluded subjects taking vitamin D
replacement. This was not a requirement in either the
Shaheen study or the current study, although Shaheen
noted only a weak relationship between supplementation
and 25 (OH)D levels. The studies also differ in their geog-
raphy. ECLIPSE recruited subject in many locations, while
Janssens evaluated subjects in Belgium. In addition, Jans-
sens included subjects with FEV1 severity stage 1, while
these milder subjects were excluded from the ECLIPSE
population. Whether the association noted by Janssens
would be present in GOLD 2e4 only was not reported.
Studies assessing the relationship between vitamin D and
severity of emphysema in humans are limited to date. An-
imal models have shown that 25(OH)D deficiency is associ-
ated with alterations in lung structure [24], but this has not
been demonstrated in humans. Dairy intake, but not spe-
cifically vitamin D intake, has been inversely associated
with severity of emphysema [25].
It is possible the relationship between FEV1 and
emphysema with vitamin D may be driven by individuals
with very marked deficiency. Stratifying our subjects into
groups based on severity of vitamin D deficiency suggests and GOLD severity.
Vitamin D lung function and structure in COPD 1585disproportionate association of the severely deficient
(<10 ng/mL) subjects with reduced FEV1 and with more
severe emphysema. This raises the possibility that the as-
sociation of low 25(OH)D with COPD may not correspond to
the current cut-off levels of deficiency (<20 ng/mL), but
rather that the association is driven by the severely defi-
cient as recently suggested by Lehouck and colleagues [11].
Our study did not demonstrate a relationship between
DBP levels and either FEV1 or emphysema. Previous studies
have shown a relationship between various DBP alleles and
COPD [26,27], and several potential mechanisms that might
explain this relationship [28e31]. DBP can directly bind to
leukocytes and modulate macrophage activation and
neutrophil chemotaxis [13]. In this regard, DBP has been
described as enhancing the chemotactic potency of C5a,
one of the key active peptides generated during comple-
ment activation. Interestingly, upon binding Vitamin D, DBP
may be less potent in this regard, providing a potential
mechanism for Vitamin D to have an “anti-inflammatory”
effect independent of binding to its canonical receptor.
Another potential mechanism could be the ability of DBP to
sequester Vitamin D. For this reason, we used standard
methods to estimate free vitamin D, based on concentra-
tions of Vitamin D and DBP. These estimates did not
correlate better with FEV1, emphysema or clinical param-
eters than the measures of Vitamin D. Although this does
not provide support for a role for free Vitamin D, direct
measurement of free vitamin D or of 1,25 (OH)D, the bio-
logically active form of vitamin D, which was beyond the
scope of this project, may have stronger associations. The
most widely used laboratory methods do not delineate free
versus bound vitamin D, and, to our knowledge free vitamin
D has not been directly measured in COPD. In our study,
calculated free vitamin D was not associated with primary
end points of lung function or emphysema, although asso-
ciations neared significance. Significant associations, how-
ever, were noted with conditions related to COPD,
including Clara cell secretory protein, 6 min walk distance,
SGRQ score and GOLD grouping.
Our study did not demonstrate a relationship between
25(OH)D levels and CT measured bone attenuation. An as-
sociation between 25(OH)D levels and bone density has
been identified in many populations [32], including pop-
ulations of COPD specifically [8,9]. Indeed, the presence of
vitamin D deficiency at baseline increased the risk of the
development of osteoporosis over a 3-year period by 7.5-
fold in COPD patients [33]. Supplementation with the
active form of vitamin D, calcitriol, showed a beneficial
effect on bone density in pulmonary patients with osteo-
porosis [34]. However, other studies have failed to confirm
the association between 25(OH)D levels and bone density in
COPD patients [35]. Interestingly, our study did find an as-
sociation between DBP and bone attenuation measure-
ments in the subjects with emphysema. Recent studies in
osteoporotic males have shown increased VDBP levels as
compared to non-osteoporotic controls [15].
In the current study, the relationship between vitamin D
and change in clinical status was not assessed. An analysis
of the Lung Health Study rapid decliners vs. slow decliners
found no relationship between vitamin D levels and rate of
change in FEV1 [36]. The current study was designed pri-
marily to assess a relationship between vitamin D andemphysema, which we demonstrated. Subjects were
selected to demonstrate a range of emphysema levels for
this reason. The severity of emphysema has been related to
the rate of lung function decline in the ECLIPSE cohort [37].
An analysis of the full ECLIPSE cohort will have more power
to explore a relationship between vitamin D and change in
measures of severity of COPD.
Our study demonstrates a relationship between vitamin D
and 6 min walking distance and disease related health status
assessed by the SGRQ. Both the SGRQ and 6 min walking
distance have been related to increased mortality in COPD
independently of FEV1, which is also related to mortality
[38,39]. Whether correction of severe vitamin D deficiency
with therapy is possible in COPDwas not tested in the current
study. However, both the SGRQ and 6 min walking distance
can be improved by specific interventions in COPD. Thus it is
reasonable to propose that these parametersmay respond to
vitamin D augmentation. No pharmacotherapy has yet been
definitively demonstrated to improve survival in COPD.
Whether vitamin D supplementation would be useful in this
regard is untested, but may be reasonable, particularly
among patients who are severely deficient.
Our study also demonstrates a relationship between
vitamin D and bronchodilator responsiveness. Prior studies in
asthma have demonstrated that lower vitamin D levels are
associated with increased airway responsiveness on meth-
acholine challenge [40]. An inverse relationship is seen be-
tween bronchodilator response and 25(OH)D levels in
asthmatic children [41,42]. Our study demonstrates the
opposite correlationof 25(OH)Dandbronchodilator response,
as we found higher levels of 25(OH)D were associated with
increased bronchodilator response. This raises the possibility
that repletion of vitamin D stores may improve treatment
responsiveness. Bronchodilator response in COPD, however,
is directly related to lung function [43]. Thus the association
of vitamin D with responsiveness may be secondary to the
relationship between vitamin D and lung function.
Vitamin D status has also been shown to be inversely
related with biomarkers of inflammation [44e46], which
may play a role in the pathogenesis of COPD. Clara cell
secretory protein (CCSP), the most abundant secretory
protein in the airway, has been shown to play a role in
inflammation, infection, and oxidative stress [47]. Serum
CCSP is reduced in COPD patients and smokers, and signif-
icantly higher in former smokers with airflow obstruction
reversibility [48]. Our study shows increased serum CCSP
levels associated with higher levels of 25(OH)D as well as
free vitamin D. Whether or not there is a mechanistic
relationship between these measures is unclear. CCSP is
produced by the epithelium of the airways. Dysfunction of
airway epithelium is thought to lead to reduced production.
A role for vitamin D in directly modulating epithelial func-
tion is plausible as several types of epithelium have been
demonstrated to express vitamin D receptors and to
respond to vitamin D [49,50]. Alternatively, vitamin D may
modulate epithelial cell function in the lung indirectly
through an effect on inflammatory cells.
It was of interest to assess vitamin D levels with respect
to the new GOLD classification. In this, a significantly lower
25(OH)D was observed in group D, which has both more
severely impaired FEV1 (stages 3e4) and/or more frequent
exacerbation history as well as more symptoms. These
1586 I. Berg et al.levels were lower than Group C, which had impaired FEV1
(stages 3e4) and/or more frequent exacerbation history
but less dyspnea on the mMRC scale, suggesting that
vitamin D deficiency may be related to symptoms inde-
pendent of the association with lung function and struc-
ture. The use of oral corticosteroids, which may play a role
in this association, was not included in the analysis.
While there are some reasons to suggest vitamin D
deficiency may contribute to the pathogenesis of COPD, it is
also possible that there is a cause and effect relationship in
the opposite direction. Specifically, patients with COPD are
less active than individuals without COPD and spend less
time in outdoor activities. Whether the behavioral impact
of COPD affects diet is relatively unexplored and could also,
conceptually, lead to a decrease in vitamin D intake in
COPD. COPD as a cause of reduced vitamin D levels is a
plausible and untested possibility. The relationships of
vitamin D levels with dietary intake, metabolism and sup-
plementation are complex and may account for the rela-
tively weak relationships that have been observed between
vitamin D and FEV1 in prior studies [4,23] and with the
clinical and biochemical measures the current study. Our
study, however, confirms the relationship between COPD
and vitamin D levels and specifically establishes a rela-
tionship between emphysema and COPD clinical features
with vitamin D.
Our study has several weaknesses. Although we adjusted
for several confounders, information on other known con-
founders of vitamin D status such as race and place of living
was not available, and therefore were not accounted for.
Information on vitamin D supplementation was not avail-
able. Also, CT scans were not performed at the exact time
as the serum used in this study due to availability of stored
samples, although CT scans for quantification of emphy-
sema were performed 6 months after serum collection. The
CT scans used to assess bone density were done 2 years
prior to the serum collection used in this study. Clinical
classification of the subjects and biomarker data were not
available at the time of the serum collection, but were
available at study baseline, 2½ years prior to serum mea-
surement. The fact that significant associations were
observed suggests that these relationships may be very
robust. Assessment at similar time points may have
revealed stronger relationships or relationships in addition
to those observed. Finally, the associations observed in the
current study between vitamin D and features of COPD do
not establish a causal relationship.Conclusion
This study provides evidence supporting the role of
vitamin D in COPD by confirming the relationship between
vitamin D and airflow. The association between emphy-
sema and 25(OH)D levels is a novel finding, suggesting the
possibility of a modulating effect of vitamin D on lung
structure. A relationship between vitamin D and bio-
markers that are believed to reflect disease activity in
COPD merit further exploration. Further studies to
elucidate the pathogenic mechanisms and interaction
between vitamin D and DBP, including the DBP genotype,
and their effect on existing therapies may characterize asubset of COPD patients that may benefit from vitamin D
supplementation.
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